人副流感病毒疫苗研究进展  

Progress in the development of human parainfluenza virus vaccines

作　　者：王环茹 房方皓 赵雪 王葳 陈敏[1] 滕峥[1] Wang Huanru;Fang Fanghao;Zhao Xue;Wang Wei;Chen Min;Teng Zheng(Institute of Microbiology Laboratory,Shanghai Municipal Center for Disease Control and Prevention,Shanghai 200336,China)

机构地区：[1]上海市疾病预防控制中心病原所,上海200336

出　　处：《中华实验和临床病毒学杂志》2023年第5期558-563,共6页Chinese Journal of Experimental and Clinical Virology

摘　　要：人副流感病毒是一种重要的呼吸道病原体,可在婴幼儿和其他免疫力低下人群中引起支气管炎和肺炎。目前全球尚无获批上市的疫苗与特异性药物可用于人副流感病毒的预防与治疗。国内外关于人副流感病毒疫苗的研究众多,本文将这些研究分为灭活疫苗、减毒活疫苗、亚单位疫苗、mRNA疫苗以及联合疫苗5个方向进行梳理,并以此为依据展开综述。Human parainfluenza virus(HPIV)is important respiratory pathogen that could cause bronchitis and pneumonia in infants,young children and other immunocompromised populations.At present,there are no vaccines or drugs approved for specific prevention and treatment of HPIV infection.In this review we introduce the development of HPIV vaccines from five categories including inactivated vaccine,live attenuated vaccine,subunit vaccine,mRNA vaccine and combined vaccine.

关 键 词：副流感病毒 疫苗 呼吸道感染 预防 

分 类 号：R392[医药卫生—免疫学]